No Data
No Data
IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma
Express News | IO Biotech Completed Enrollment In Its Neoadjuvant/Adjuvant Phase 2 Basket Trial Of Therapeutic Cancer Vaccine Candidate, In Combination With Merck's Keytruda (Pembrolizumab), Initial Data Expected In 2025
Express News | IO Biotech Completes Enrollment in Phase 2 Trial of Its Investigational, off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients With Resectable Melanoma or Head and Neck Cancer
Express News | IO Biotech Inc - Receives Nasdaq Notice for Minimum Bid Price Non-Compliance
Insider Purchase: Chief Executive Officer of $IOBT (IOBT) Buys 12,500 Shares
IO Biotech Secures €57.5 Million EIB Loan Facility
Unlock the Full List